What should you pay special attention to when using trametinib tablets?

Trametinib has shown some important warnings and precautions in clinical studies, including new primary malignancies, bleeding, colitis, gastrointestinal perforation, venous thromboembolic events, cardiomyopathy, ocular toxicity, interstitial lung disease/pneumonitis, severe febrile reactions, skin reactions, hyperglycemia, hemophagocytic lymphohistiocytosis, and embryo-fetal toxicity.

1. New primary malignant tumors increased in patients treated with trametinib in combination with dabrafenib. Among them, cutaneous squamous cell carcinoma occurs in 2% of patients, basal cell carcinoma accounts for 3%, and new melanoma occurs in <1% of patients. Therefore, dermatological evaluation is recommended before treatment and every two months during treatment, with continued monitoring for 6 months after discontinuation of the combination.

2. Regarding bleeding events, trametinib may cause a variety of bleeding conditions including severe gastrointestinal bleeding and cerebral hemorrhage, and even death cases have been reported. For all grade 4 bleeding events and grade 3 bleeding events that fail to improve, trametinib should be discontinued immediately and permanently.

3. Although the incidence rates of colitis and gastrointestinal perforation are low (both<1%), close monitoring is still required to ensure timely treatment of related symptoms. Venous thromboembolic events are also a potential risk, and patients who develop symptoms of deep vein thrombosis (DVT) or pulmonary embolism (PE) should seek immediate medical attention.

4.The risk of cardiomyopathy cannot be ignored, including heart failure. It is recommended to monitor left ventricular ejection fraction (LVEF) before the start of treatment and regularly during treatment, so that abnormalities can be detected and dealt with in a timely manner. In addition, ocular toxicity manifests as retinal vein occlusion and retinal pigment epithelial detachment. Patients who develop visual impairment need to undergo ophthalmological evaluation and permanently discontinue the drug if RVO is discovered.

5. Regarding interstitial lung disease (ILD) and pneumonia, trametinib should be suspended when new pulmonary symptoms appear, and it needs to be permanently discontinued after diagnosis. Severe febrile reactions are also a major concern. If the body temperature reaches or exceeds 38°C, trametinib needs to be discontinued and other necessary measures must be taken to control body temperature.

6. In terms of skin reactions, serious skin adverse reactions may occur during treatment, including extremely critical conditions such asStevens-Johnson syndrome, so monitoring is required. At the same time, for patients with existing diabetes or hyperglycemia, blood glucose levels need to be monitored regularly during treatment, and anti-hyperglycemic drugs should be adjusted according to medical advice.

7. In addition, hemophagocytic lymphohistiocytosis (HLH) If suspected, treatment should be discontinued and appropriate treatment should be carried out after confirmation. For pregnant women, trametinib is embryotoxic, so effective contraceptive measures must be used during treatment and within 4 months thereafter to reduce potential risks to the fetus.

Overall, during the use of trametinib, the medical team needs to conduct comprehensive monitoring and management of patients to ensure timely identification and treatment of various adverse reactions that may occur, thereby ensuring patient safety and efficacy. When using this drug, patients should maintain good communication with their doctors, promptly report any abnormal symptoms, and ensure that they receive appropriate medical guidance.

Reference materials:https://go.drugbank.com/drugs/DB08911